ABSTRACT: Background. The purpose of this study was to compare the effect of cetuximab-based radiotherapy (RT) with cisplatin-based concomitant chemoradiotherapy (CCRT) on artificial nutrition dependence in locoregional advanced head and neck cancer. Methods. We identified patients treated with cetuximab-based RT or CCRT between 2012 and 2014 in a Japanese national database, and used propensity score-matched analyses to evaluate artificial nutrition dependence for 30 days after starting chemotherapy and at hospital discharge. Results. Of 3935 eligible patients, propensity score matching generated 250 pairs. Thirty-day artificial nutrition dependence was significantly lower in the cetuximab-based RT group than in the CCRT group (25.6% vs 35.2%; odds ratio [OR] 5 0.67; 95% confidence interval [CI] 5 0.46-0.97; p 5 .036). No significant difference in artificial nutrition dependence at hospital discharge was shown (6.2% vs 7.2%; OR 5 1.07; 95% CI 5 0.52-2.17; p 5 .861). Difference in duration of hospitalization was insignificant. Conclusion. Cetuximab-based RT may reduce short-term artificial nutrition dependence compared to CCRT.
INTRODUCTION
Cetuximab is an immunoglobulin G1 monoclonal antibody to epidermal growth factor receptor, which is overexpressed in a majority of head and neck squamous cell carcinomas. 1 In the past decade, cetuximab has been approved for treating squamous cell carcinoma of the head and neck in the United States and European Union. 1, 2 In Japan, cetuximab is approved for use only for patients with unresectable locally advanced head and neck cancer or recurrent cancer. Cetuximab-based radiotherapy (RT) is reported to improve locoregional control and reduce mortality in locally advanced and unresectable head and neck cancer without increasing adverse events compared to RT alone. 3 Conventional treatment for head and neck cancer is cisplatin-based concomitant chemoradiotherapy (CCRT), the first member of a class of platinum-containing anticancer drugs. Studies have shown that CCRT improves locoregional control and survival time, but often produces acute adverse effects. 4, 5 Previous observational studies and phase II clinical trials have suggested that patients treated with CCRT suffered from neutropenia, anemia, thrombocytopenia, and radiation dermatitis compared with those treated with cetuximab-based RT, whereas patients treated with cetuximab-based RT suffered from skin acne and radiation dermatitis compared with those treated with CCRT. 6, 7 Patients with severe CCRT-associated complications cannot receive oral nutrition, and must instead receive enteral tube feeding using a nasogastric or percutaneous endoscopic gastrostomy (PEG) tube, or parenteral nutrition with intravenous hyperalimentation. [8] [9] [10] Feeding tubes may impair quality of life in patients with head and neck cancer, potentially resulting in reduced survival. 11 No phase III clinical trial to date has compared cetuximab-based RT with CCRT in terms of the occurrence of severe complications in locally advanced head and neck cancer. Although some evidence suggests a potential advantage of cetuximab-based RT on reducing enteral or parenteral nutrition dependence compared with CCRT, 12, 13 these studies lacked adjustment for patient characteristics because of small sample size.
In the present study, we analyzed data from a large population of patients with head and neck cancer using a national database in Japan, and performed propensity score-matching analysis to balance background characteristics and compare the occurrence of artificial nutrition dependence between patients receiving cetuximab-based RT and CCRT.
MATERIALS AND METHODS

Data source
The present study utilized the Diagnosis Procedure Combination database, a national administrative claims and discharge abstract database that includes data from approximately 7 million patients, representing more than half of all inpatient admissions to acute care hospitals in Japan. Approximately 1000 hospitals contribute data to the Diagnosis Procedure Combination database, including voluntary participating community hospitals and all 82 academic hospitals in Japan. The database includes the following patient information: (1) demographic characteristics; (2) main diagnoses, comorbidities at admission, and complications after admission, recorded in accordance with the International Classification of Diseases, 10th Revision (ICD-10) codes; (4) surgical procedures indexed with the Japanese original codes; (5) drugs and devices used; and (6) type of hospital (academic or nonacademic). The Institutional Review Board at The University of Tokyo approved the study protocol. The requirement for informed consent was waived because of the retrospective observational design of the study and the use of anonymous data.
Patients
We identified patients diagnosed with head and neck cancer (ICD-10 codes C00-C06, C09-C10, C12-C14, C32, C411, and C440) between December 2012 and March 2014, as cetuximab was approved for use in Japan for unresectable or relapsed head and neck cancer on December 2012.
14 Of this population, we selected the admission data that patients received cetuximab concomitant RT (the cetuximab-based RT group) or cisplatin-based CCRT (CCRT group) for the first time during the interval of analysis. In Japan, most patients receive primary chemoradiotherapy during hospitalization. We excluded patients based on the following criteria: patients younger than 18 years old; patients who died during hospitalization; patients who were discharged to other hospitals; patients who started artificial nutrition before initiation of CCRT or cetuximabbased RT; and patients who were treated with both cetuximab and cisplatin during the same hospitalization period. We excluded patients with recurrent cancer because of the increased risk for artificial nutrition with chemoradiotherapy, compared with patients with nonrecurrent cancer. To identify patients with unresectable cancer, we excluded patients who underwent tumor resection and patients with clinical cancer under stage III 15 in the CCRT group because these patients had no possibility to receive cetuximab-based RT according to approval for use for cetuximab. For advanced head and neck cancer, tumor resection was reported to be the most effective surgery and recommended primary treatment according to the National Comprehensive Cancer Network guidelines for head and neck cancer. 16 Nevertheless, patients with advanced head and neck cancer who had not undergone tumor resection were identified as patients with unresectable cancer in this study.
Outcomes
The primary outcomes of the study included binary outcomes of (i) artificial nutrition dependence for 30 days after starting chemotherapy and (ii) artificial nutrition dependence at hospital discharge. Artificial nutrition was defined as enteral feeding using a nasogastric or PEG tube, or parenteral feeding with intravenous hyperalimentation. Patients who required artificial nutrition for 30 days were regarded as "artificial nutrition dependence for 30 days" 5 1, and those who ceased artificial nutrition within 30 days were regarded as "artificial nutrition dependence for 30 days" 5 0. "Artificial nutrition dependence at discharge" was the status attributed to those requiring artificial nutrition even after discharge from the hospital.
Secondary outcomes were (i) receipt of PEG procedure during hospitalization, (ii) length of hospital stay, and (iii) the number of radiation fractions received during hospitalization. The database does not include data on doses of radiation, therefore, data on the number of radiation fractions were evaluated instead.
Propensity-score matching
We performed propensity-score matching between cetuximab-based RT and CCRT groups based on the estimated propensity score for each patient. To estimate the propensity score, we fitted a logistic regression model for cetuximab-based RT treatment as a function of patient demographics, treatments, and hospital factors. Demographic factors included age (60 years, 61-70 years, and >70 years), sex, body mass index (<18. , primary tumor site (oral mucosa, mandible or maxilla, and larynx or pharynx), advanced tumor clinical classification (cT4a or cT4b), lymph node metastasis (cN1), smoking status (nonsmoker, or current/ex-smoker), Charlson comorbidity index (0-2 or 3), and comorbidities (hypertension, diabetes mellitus, ischemic heart disease, chronic heart failure, renal failure, chronic obstructive pulmonary disease, and pneumonia). Comorbid patients with diabetes mellitus were defined as those who took one or more oral hypoglycemic agent, or those who were treated with insulin during hospitalization. We used ICD-10 codes to identify patients with hypertension (I10 or I15), ischemic heart disease (I20-I25), heart failure (I50), renal failure (N17-N19), chronic obstructive pulmonary disease (J44), pneumonia (J18, J69, J84), and reflux esophagitis (K21) on admission. Treatment factors included emergency admission, intensity-modulated radiotherapy, and combination chemotherapy of taxane and fluorouracil, and induction chemotherapy. Patients who received taxane or fluorouracil the day before or more than 21 days after initiation of RT were considered as having received induction chemotherapy. 17, 18 Hospital factors included the type of hospital and hospital volume. Hospital volume was defined as the average number of patients at each hospital who received chemoradiotherapy for head and neck cancer per year. It categorized into tertiles of low (9.7/year), medium (9.8-22.3/year), and high (22.4/year) volume groups to ensure almost equal numbers of patients in the 3 categories.
To measure goodness-of-fit of the model, c-statistics were calculated. We performed a one-to-one matched analysis using nearest-neighbor matching with 0.2 SDs of the logit of the propensity score as the caliper value, without replacement methods. To test the covariate balance after propensity-score matching, we calculated standardized differences to compare the baseline characteristics of patients between the cetuximab-based RT and CCRT groups for both unmatched and propensity score-matched groups. A standardized difference of >10% was defined as out of balance.
Statistical analysis
The proportions of PEG procedures performed during hospitalization were compared using the chi-square test between cetuximab-based RT and CCRT groups in the matched groups. Length of stay and number of radiation fractions were compared using a t test. In the propensity score-matched groups, we conducted logistic regression analyses to compare (i) artificial nutrition dependence for 30 days after starting chemotherapy and (ii) artificial nutrition dependence at hospital discharge between the cetuximab-based RT and CCRT groups, with adjustment for the number of radiation fractions. These regression analyses were fitted with generalized estimating equations to account for the paired nature of the cetuximab-based RT and CCRT groups. We also performed subgroup analyses for patients treated with taxane or fluorouracil and untreated to assess differences in artificial nutrition dependence at 30 days and at hospital discharge between cetuximab-based RT and CCRT using a chi-square test. The threshold for significance was a p value .05. All analyses were performed using IBM SPSS Statistics version 22.0 (IBM, Armonk, NY) and STATA version 13.0 (StataCorp, College Station, TX).
RESULTS
We extracted data on 11,739 patients with head and neck cancer with cetuximab or cisplatin concomitant radiotherapy during the study period. Of these, 7804 patients were excluded according to the exclusion criteria and the remaining 3935 patients were identified as eligible for the study (see Figure 1 ). These patients were categorized into cetuximab-based RT (n 5 380) or CCRT (n 5 3555) groups, and 250 pairs were generated using propensity-score matching. The c-statistic for goodnessof-fit was 0.91 (95% confidence interval [CI] 5 0.89-0.92) in the propensity-score model.
Baseline characteristics of patients in the unmatched and propensity score-matched groups are described in Table 1 . Patients were more likely to receive cetuximabbased RT if they had the following characteristics: older age, oral mucosa carcinoma, less advanced cancer, no lymph node metastasis, renal failure, emergency admission, recurrent cancer, lower hospital volume, or combination chemotherapy. In the propensity score-matched groups, the absolute values of the standardized difference were <10% for all baseline characteristics. Table 2 shows the average length of hospital stay, the number of radiation fractions, and the proportion receiving PEG procedures during hospitalization. The average length of hospital stay did not differ significantly between the cetuximab-based RT and CCRT groups in the propensity score-matched group (64.5 days vs 62.7 days; p 5 .58). The average number of radiation fractions in the cetuximab-based RT group was significantly less than in the CCRT group (26.3 fractions vs 28.9 fractions; p 5 .023). The proportion of patients who underwent a PEG procedure during hospitalization in the cetuximab-based RT group was not significantly lower than in the CCRT group (10.0% vs 14.4%; p 5 .17). Table 3 shows the proportion of (i) artificial nutrition dependence for 30 days after starting chemotherapy and (ii) artificial nutrition dependence at hospital discharge, as well as the results of the multivariable logistic regression analyses. The cetuximab-based RT group had a significantly lower proportion of artificial nutrition dependence for 30 days than the CCRT group (25.6% vs 35.2%; odds ratio [OR] 5 0.67; 95% CI 5 0.46-0.97; p 5 .036). The proportion dependent on artificial nutrition at hospital discharge was not significantly different between the cetuximab-based RT and CCRT groups (6.2% vs 7.2%; OR 5 1.07; 95% CI 5 0.52-2.17; p 5 .861). The number of radiation fractions was significantly associated with the outcomes. The difference in 30-day artificial nutrition dependence between cetuximab-based RT and CCRT was significant for patients who had not received taxane or fluorouracil, but was not significant for patients who had. No significant difference in artificial nutrition dependence at hospital discharge was shown between cetuximab-based RT and CCRT in both subgroups.
DISCUSSION
We retrospectively evaluated the complications of cetuximab plus concomitant RT compared with cisplatinbased chemoradiotherapy using propensity-score matching analyses. The results suggest that cetuximab-based RT was significantly associated with reduction in artificial nutrition dependence for 30 days after starting chemotherapy in patients with unresectable head and neck cancer. The difference in the length of hospital stay, the number of radiation fractions, and the incidence of percutaneous endoscopic gastrostomy procedures between cetuximab-based radiotherapy and concomitant chemoradiotherapy in propensity score-matched pairs (n 5 500).
Propensity score-matched groups Abbreviations: RT, radiotherapy; CCRT, concomitant chemoradiotherapy; Diff, difference; CI, confidence interval; PEG, percutaneous endoscopic gastrostomy.
However, no significant difference in artificial nutrition dependence at discharge was shown between the cetuximab-based RT and CCRT groups. The numbers of radiation fractions were significantly associated with artificial nutrition dependence for 30 days and artificial nutrition dependence at hospital discharge. In previous studies, the proportions of patients with enteral nutrition dependence varied widely, from 36% to 78% after CCRT [8] [9] [10] 19 and from 38% to 79% after cetuximab-based RT. 20, 21 The proportion of patients who failed to wean from artificial nutrition has been reported as 22% with both cetuximab-based RT and CCRT at 30 days after the end of treatment. 22 A previous study showed that CCRT increased the risk of enteral nutrition dependence at 6 months compared to cetuximab-based RT. 23 The proportion of patients receiving the PEG procedure during hospitalization was reported as 50% to 55% in cetuximab-based RT and 69% to 78% in CCRT. 5, 12, 13, 19 Previous studies reported that enteral nutrition dependence was significantly associated with advanced tumor classification, severe weight loss (>10% from baseline), chemoradiotherapy, and high doses of RT. [23] [24] [25] [26] In our study, findings on the proportion of patients with artificial nutrition dependence for 30 days after starting chemotherapy and the significant association between high doses of RT and the occurrence of artificial nutrition dependence were consistent with previous studies. However, the proportion of patients discharged with artificial nutrition dependence or subjected to a PEG procedure during hospitalization was lower than that of previous studies.
Artificial nutrition dependence associated with anticancer treatment is regarded as a severe adverse effect for patients during or after treatment. The use of a feeding tube has been reported to impede the resumption of normal oral eating, 8 as limitations in oral intake prompted disuse atrophy and adverse remodeling of aerodigestive tract muscle, even if the interval of disuse was brief. 24 Patients also had impaired nutritional status, even though vomiting, nausea, and mucositis were reversible. 21 A decline in patient nutritional status impaired immune function and increased dehydration and hospitalization period. 8 Furthermore, feeding tube dependence was the most negative clinical effect on quality of life in patients with head and neck cancer as a result of significantly reduced eating, speech, and social function. 11 Low quality of life after treatment has been reported to impair long-term survival in patients with head and neck cancer. 27 For these reasons, efforts should be made to avoid the initiation of artificial nutrition during or after chemoradiotherapy.
Cetuximab-based RT is likely to be initiated in patients unsuitable for CCRT for reasons of age (>70 years), impaired organ function, or poor performance status in a practical setting. 6, 12, 19 Nevertheless, previous studies have not accounted for differences in patient characteristics between cetuximab-based RT and CCRT. Our study used a robust statistical method to adjust for patient background by propensity-score matching, and indicated that cetuximab-based RT was associated with decreased occurrence of artificial nutrition or PEG placement during hospitalization compared to CCRT.
A previous study showed a strong association between the number of radiation fractions and dysphagia. 25 In the present study, we included the number of radiation fractions into the multivariable regression model. Even after adjustment for the number of radiation fractions, cetuximabbased RT was associated with a significantly lower incidence of artificial nutrition dependence than CCRT.
The numbers of fractions were significantly different between the cetuximab-based RT and CCRT groups in the present study, although we believe the difference to be clinically insignificant. Furthermore, a previous study reported no significant difference in the interruption of RT between cetuximab-based RT and CCRT groups because of complications of chemoradiotherapy. 6 Our findings offer a new insight on initiating cetuximab-based RT or CCRT for locoregional advanced head and neck cancer. As insufficient evidence has been provided from previous phase III trials, differences in efficacy between cetuximab-based RT and CCRT remain controversial. A meta-analysis of retrospective studies showed a possible superiority of platinum-based chemoradiotherapy over cetuximab-based RT in terms of overall survival, progression-free survival, and locoregional relapse. 7 However, a recent phase II trial reported no significant difference in efficacy. 22 Regarding complications of the 2 treatments, our study provides new evidence on a lower probability of artificial nutrition dependence in cetuximab-based RT. A randomized phase III trial (Radiation Therapy Oncology Group 1016) comparing cetuximab and cisplatin as radiosensitizers in oropharyngeal cancer has been ongoing since 2011, and will assess feeding tube rates at 1 year after randomization in addition to overall survival, acute toxicities, and late toxicities. This study is expected to increase understanding of the effectiveness of cetuximab-based RT compared to CCRT in the treatment of head and neck cancer. The present study was not without limitations. First, it was a retrospective observational design. Second, the database did not contain detailed information on the volume of artificial nutrient received, baseline weight loss, laboratory data, histologic diagnosis, or the amount of chemotherapy administered. We could not distinguish between artificial nutrition alone and oral nutrition with supportive artificial nutrition. We also failed to differentiate between therapeutic artificial nutrition and prophylactic artificial nutrition for avoiding weight loss and decreased serum albumin. The CCRT arm of the study was not limited to patients with squamous cell carcinoma histology. Our data did not include information on the amount of chemotherapy administered, which may have had an influence on patient nutritional status. Third, the heterogeneity of the radiosensitizing regimens between induction chemotherapy and concurrent chemotherapy could not be assessed because therapy was implemented for only 5 patients in the propensity-matched group. However, the National Comprehensive Cancer Network guidelines do not recommend induction chemotherapy as a clear advantage in overall survival has not been shown and the incidence of severe toxicities may be increased compared to concurrent chemoradiotherapy. 16 Forth, the c-statistic for goodness-offit (0.91) was slightly too high to allow our results to be generalized to patients outside of the score-matched groups. Finally, the current study was unable to evaluate long-term feeding tube dependency because our database did not include any data after hospital discharge.
In conclusion, we found a significant reduction in the occurrence of artificial nutrition dependence in patients with unresectable head and neck cancer treated with cetuximabbased RT compared to CCRT. The results imply that cetuximab-based RT is relatively safe compared to CCRT, in terms of lower risk of artificial nutrition dependence.
